For men with intermediate-risk prostate cancer, a trial reveals improvements in several clinical outcomes.

Published Date: 03 May 2023

The primary endpoint of the phase 3 NRG Oncology RTOG 0815 clinical study, which compared dose-escalated radiotherapy (RT) alone to dose-escalated RT with short-term androgen deprivation (STAD), was not met.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot